Anti-interferon alpha antibodies and autoantibodies in patients with Beh double dagger et's disease uveitis treated with recombinant human interferon alpha-2a
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, cilt.253, sa.3, ss.457-465, 2015 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 253 Sayı: 3
- Basım Tarihi: 2015
- Doi Numarası: 10.1007/s00417-014-2856-3
- Dergi Adı: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.457-465
- Anahtar Kelimeler: Behcet's disease, Interferon, Anti-interferon alpha antibody, Binding antibody, Autoantibody, CHRONIC HEPATITIS-C, LONG-TERM EFFICACY, BEHCETS-DISEASE, MULTIPLE-SCLEROSIS, AUTOIMMUNE-DISEASE, NEUTRALIZING ANTIBODIES, BETA ANTIBODIES, THERAPY, SAFETY, PANUVEITIS
- İstanbul Üniversitesi Adresli: Evet
Özet
Recombinant human (rh) interferon alpha2a (IFN-alpha 2a) therapy is successfully used for the treatment of Beh double dagger et's disease (BD) uveitis refractory to conventional immunosuppressive treatment.